Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 139Carcinoma, Intraductal, Noninfiltrating 8Neoplasm Metastasis 6Breast Carcinoma In Situ 5Breast Neoplasms, Male 4Breast Diseases 4Arthralgia 4Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Endometrial Neoplasms 3Advanced Breast Cancer 3Neoplasms 2Breast Cancer Metastatic 2Solid Tumor 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Seizures 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Pain 1Osteoporosis 1Obesity 1Muscle Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Locoregional Recurrence 1Invasive Breast Cancer 1Hypogonadism 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1

Interventions

palbociclib 1exemestane 1Letrozole 1Hydroxychloroquine 1BID protein, human 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer × Anastrozole × Clear all
NCT07061717 2025-07-11

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Not yet recruiting
474 enrolled
Breast

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡